Clinical trial

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

NCT01894516

Study summary

ClinicalTrials.gov

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention GLPG0634 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-10-08

PhasePHASE2

Conditions

Rheumatoid Arthritisverified · MONDO: rheumatoid arthritis

Interventions

GLPG0634DRUG

PlaceboDRUG

Sponsors & collaborators

Lakefront Biotherapeutics NVlead sponsor

Mapped research locations

BucharestRomania3 BogotáColombia3 WarsawPoland2 BudapestHungary2 KrakowPoland2 HoustonTexas, United States1 BerlinGermany1 PhoenixArizona, United States1 Oklahoma CityOklahoma, United States1 AustinTexas, United States1 CharlestonSouth Carolina, United States1 HamburgGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01894516 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.